Search
Experts from MSK explain why seed oils are actually an important part of a healthy diet.
An international phase 3 trial has found that polatuzumab vedotin improves outcomes for patients with newly diagnosed diffuse large B cell lymphoma.
NEW YORK, September 21, 2003 - New research from Memorial Sloan Kettering Cancer Center (MSKCC), Cornell University, and The University of Connecticut describes a novel way of producing therapeutic nerve cells that can cure mice with Parkinson's-like disease. The work, which will be published in the October issue of Nature Biotechnology (available online September 21), provides the first evidence that cloned cells can cure disease in an animal model.
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Richard J. O’Reilly, MD, was named to the Ninth Annual Giants of Cancer Care®.
Structural biologists at Memorial Sloan Kettering Cancer Center are collaborating with biochemists and cell biologists at The Rockefeller University to study how cells read genetic instructions imprinted on histones, DNA's packaging proteins.
In this Q&A, MSK hematologic oncologist Sergio Giralt, MD, talks about a phase 3 trial of ide-cel CAR T therapy for people with recurrent multiple myeloma and what it may mean for people with this hard-to-treat blood cancer.
The awards are given annually to people in an array of fields in the arts and sciences.
A passion for both science and the humanities has informed the life and career of Dr. Ivan Maillard, who was recently selected to lead the Division of Hematologic Malignancies at MSK.
Gynecologic cancer surgeon Carol Brown featured in Crain's New York Business’ Notable Black Leaders and Executives list.